BioSpace

Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled

Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”

By BioSpace

1 min read
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights